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A B S T R A C T
Drug-induced torsades de pointes (TdP), a life-threatening polymorphic ventricular 
tachycardia associated with prolongation of the QT interval, has been the main safety 
reason for the withdrawal of non-cardiac agents from clinical use over the last dec-
ade. This complication is commonly referred to as drug-induced proarrhythmia. The 
present review highlights and puts emphasis on the mechanisms underlying the drug-
induced QT interval prolongation and TdP as well as on the identification of easily 
recognized risk factors that predispose to this potentially life-threatening condition.
I N T R O D U C T I O N
A continuously rising number of non-antiarrhythmic agents have been shown to 
prolong cardiac repolarization predisposing to a certain type of polymorphic ventricular 
tachycardia termed torsades de pointes (TdP) and sudden cardiac death.1-5 Drug-
induced QT interval prolongation is considered the most frequent cause of withdrawal 
or relabeling of marketed drugs in the last decade, but this adverse drug reaction is 
assumed to be rare (less than one in 100 000).5 Drugs with proven lengthening of the 
QT interval or a definite association with TdP are common and are estimated to con-
stitute approximately 2-3% of all prescriptions written.6 Antibiotics and psychotropic 
drugs are the most common non-cardiac drugs involved in drug-induced QT interval 
prolongation, which in the vast majority of cases are prescribed by non-cardiologists.1,5,7 
Drugs implicated in QT interval prolongation and TdP are listed in Table 1. The 
prescription of non-cardiac QT-prolonging agents has been recently associated with a 
significantly increased risk of sudden cardiac death in the general population. The risk 
of death has been shown to be higher in women and in recent starters.8 However, the 
likelihood of drug induced TdP is difficult to be predicted in routine clinical practice. 
The present review describes the underlying mechanisms of drug-induced QT interval 
prolongation and TdP as well as the risk factors that predispose to this potentially 
life-threatening condition.
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e C G  M A R K e R S  O F  v e N T R I C U L A R 
R e P O L A R I Z A T I O N
The QT interval is considered as the electrocardiographic 
(ECG) index of ventricular repolarization. Correct measure-
ment of the QT interval is of paramount importance for the 
diagnosis of drug-induced QT interval prolongation. Most phy-
sicians, including many cardiologists, cannot recognize a long 
QT interval. Viskin et al 9 have shown that correct classification 
of the QT interval as either “long” or “normal” was achieved 
by 96% of QT experts and 62% of arrhythmia experts, but by 
less than 25% of cardiologists and non-cardiologists. The QT 
interval is measured from the beginning of the QRS complex 
to the end of the T wave on the surface ECG. Despite the fact 
that there are no sufficient data regarding which lead or leads 
to use for QT interval measurement, lead II is considered the 
appropriate one because the vectors of repolarization result 
in a long single wave rather than discrete T and U waves.10 
U waves should be ignored in QT measurements. However, 
whether total repolarization time should include the entire 
QU complex still remains a subject of controversy. The QT 
interval is influenced by the heart rate. Rate acceleration 
normally leads to QT shortening, whereas bradycardia leads to 
QT lengthening.11 The RR interval preceding the QT interval 
should be measured for rate correction.11,12 Several formulas 
may be used to correct the QT interval (QTc). The most com-
monly used formulas are Fridericia’s cube root formula (QTc 
= QT/RR1/3) and Bazett’s square root formula (QTc=QT/
RR1/2). Fridericia’s equation is preferred at extremes of physi-
ological heart rate.11,12 Apart from heart rate, the duration of 
the QT interval is also influenced by sympathovagal activity, 
drugs, genetic abnormalities, electrolyte disorders, cardiac or 
metabolic diseases and changes of cardiac afterload.12 These 
intra-patient variations in the QT interval cannot be captured 
on a single twelve-lead ECG, which may be taken to evaluate 
the effect of a drug on the QT interval. Isolated measurements 
of the QT interval without reference to these complicated 
QT dynamics can lead to inaccurate estimations of the risk of 
TdP. For these reasons, the intra-patient variability in the QT 
interval can be appreciated by examining ambulatory Holter 
recordings. As shown in Table 2, QTc values greater than 450 
ms in men and 470 ms in women are considered abnormal. 
Values ranging between 430-450 ms in men and 450-470 ms 
in women are considered borderline.12 The QTc interval is 
the best available predictor of TdP episodes.13 The majority 
of drug-induced TdP occur with QTc values of more than 500 
ms.14 Data from patients with congenital long QT syndrome 
(LQTS) have shown that a QTc interval greater than 500 ms 
is related to an increased risk for arrhythmic events.15 There is 
not a clear, linear incremental relationship between QTc pro-
longation and the risk of TdP, although the TdP risk tends to be 
TABLe 1. Drugs implicated in drug-induced long QT 
syndrome.
Category Drugs 
Antiarrhythmics Disopyramide, procainamide, quinidine, 
mexiletine, propafenone, flecainide, 
d,l-sotalol, amiodarone, bretylium, 
dofetilide, ibutilide, azimilide, ajmaline
Antimicrobials Erythromycin, clarithromycin, 
azithromycin,
levofloxacin, moxifloxacin, sparfloxacin, 
gatifloxacin, grepafloxacin, trimethoprim-
sulfamethoxazole, pentamidine, quinine, 
itraconazole, ketoconazole, fluconazole, 
chloroquine, halofantrine, mefloquine, 
amantadine, spiramycin
Antihistamines Astemizole, diphenhydramine, ebastine, 
terfenadine, hydroxyzine
Antidepressants Doxepin, venlafaxine, fluoxetine, 
desipramine, imipramine, clomipramine, 
paroxetine, sertraline, citalopram
Antipsychotics Chlorpromazine, prochlorperazine,
trifluoperazine, fluphenazine, felbamate,
haloperidol, thioridazine, droperidol, 
mesoridazine, pimozide, risperidone, 
quetiapine, ziprasidone, lithium, 
chloral hydrate, pericycline, sertindole, 
sultopride, zimeldine, maprotiline
Anti-migraine Naratriptan, sumatriptan, zolmitriptan
Bronchodilators Albuterol, salmeterol
Diuretics Indapamide, thiazide, furosemide
Gastrointestinal
stimulants
Cisapride, metoclopramide, domperidone
Hormones Octreotide, vasopressin
Immunosuppressives Tacrolimus
Others Arsenic trioxide, aconitine, 
veratridine, vincamine, terodiline, 
budipine, tizanidine tiapride, cocaine, 
organophosphorus compounds
TABLe 2. Bazett-corrected QT values.
Males Females
Normal <430 ms <450 ms
Borderline 430-450 ms 450-470 ms
Prolonged >450 ms >470 ms
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clearly higher at the extremes of QT prolongation. Therefore, 
there is no established threshold below which prolongation of 
the QTc interval is considered free of proarrhythmic events. In 
terms of QTc change from baseline on treatment, it has been 
recommended that an increase of 30 ms is a potential cause 
for concern and that a 60 ms increase is a definite cause for 
concern.16 Additionally, QT dispersion (defined as the differ-
ence between the maximum and minimum QT interval of the 
12-leads) greater than 100 ms is considered abnormal.16
New ECG markers of ventricular repolarization including 
the Tpeak-end interval and the Tpeak-end/QT ratio are still 
under investigation. The Tpeak-end interval in precordial 
leads is considered as an index of transmural dispersion of 
repolarization, while the Tpeak-end interval measured in 
limb leads is more likely to reflect global dispersion, including 
apico-basal and inter-ventricular dispersion of repolarization.17 
The Tpeak-end interval has been reported to be prolonged 
in congenital LQTS and to predict TdP in acquired LQTS.18 
yamaguchi et al 19 have demonstrated that the Tpeak-end/QT 
ratio is a better predictor of TdP as compared to QTc interval 
and QT dispersion in patients with acquired LQTS. In their 
study, Tpeak-end/QT ratio greater than 0.28 was strongly as-
sociated with risk of developing TdP.19
M e C H A N I S M S  O F  D R U G - I N D U C e D 
Q T  I N T e R v A L  P R O L O N G A T I O N  A N D 
T O R S A D e S  D e  P O I N T e S
At a cellular level, the repolarization phase is driven pre-
dominantly by the outward movement of potassium ions. Two 
important potassium currents participating in ventricular repo-
larization are the components of the delayed rectifier current, 
IKr (rapid) and IKs (slow). The majority of non-cardiac QT-
prolonging agents exhibit direct electrophysiological effects on 
the rapidly activating delayed rectifier IKr current encoded by 
the human ether-a-go-go related gene (HERG, now termed 
KCNH2).1,5 However, many drugs block multiple cardiac ion 
channels (IKr, IKs, INa) leading to a more complex shift of 
action potential morphology.1,5 IKr blockade leads to a delay 
in phase 3 of repolarization of the action potential (reflected 
as QT interval prolongation on surface ECG). Activation 
of inward depolarizing currents (most likely L-type calcium 
channels or sodium-calcium exchange current) may then give 
rise to early afterdepolarizations that appear as depolarizing 
oscillations in membrane voltage during phases 2 and 3 of 
the action potential.20-22 Early afterdepolarizations that reach 
the threshold voltage cause ventricular extrasystoles. These 
phenomena are more readily induced in the His-Purkinje 
network and also in M cells from the mid ventricular myo-
cardium.20-22 Compared to subendocardial or subepicardial 
cells, M cells show much more pronounced action potential 
prolongation in response to IKr blockade.20-22 The resultant 
heterogeneity in ventricular repolarization creates a zone of 
functional refractoriness in the mid myocardial layer, which is 
probably the basis of the re-entry that is sustaining the TdP.20-22 
A “short-long-short” sequence (an extrasystole, followed by 
a post-extrasystolic pause) precedes the onset of TdP in most 
cases.23 Furthermore, pharmacokinetic interactions with drugs 
known to inhibit cytochrome P450 isoenzymes (CyP3A4 or 
CyP2D6) enhance the torsadogenic potential of these agents 
by decreasing their clearance.1,5,20 CyP3A4 activity can be 
inhibited by a wide variety of drugs including some macrolide 
antibiotics, ketoconazole and related antifungal agents, ci-
metidine, fluoxetine, protease inhibitors, and amiodarone. 
In addition, many non-drug factors, including age, smoking, 
hepatic disease, genetic polymorphisms and grapefruit juice 
may lead to CyP3A4 inhibition.7 Finally, cytochrome P450 
CyP2D6 is functionally absent in approximately 7% of white 
and black individuals (poor metabolizer group) because of loss 
of function gene variants.24
R I S K  F A C T O R S  F O R  D R U G - I N D U C e D  Q T 
I N T e R v A L  P R O L O N G A T I O N  A N D  T D P
The susceptibility of drug-induced QT interval prolon-
gation varies significantly among individuals. The unifying 
concept of “reduced cardiac repolarization reserve” has been 
proposed to explain the mechanism by which some patients are 
rendered more susceptible than others to the QT-prolonging 
effects of drugs.5,20,21 Silent mutations and/or polymorphisms 
in genes encoding cardiac ion channels leading to a reduced 
cardiac repolarization reserve hold the key to understand-
ing why healthy individuals will be exposed to risk for LQTS 
when taking medication for unrelated causes 5,20,21,25,26 Genetic 
analyses have identified the subclinical congenital form in 
5-10% of patients with drug-induced LQTS.26 Mutations have 
been reported in KCNQ1, KCNH2, KCNE1, KCNE2 and 
SCN5A genes.5,20,21,25,26 Therefore, the administration of an 
IKr current blocking agent may significantly prolong the QT 
interval in these silent carriers predisposing them to TdP and 
sudden cardiac death. The likelihood of drug-induced LQTS 
is difficult to be predicted in routine clinical practice. How-
ever, clinical history may reveal well-established risk factors 
that act as “effect amplifiers” making an otherwise relatively 
safe drug dangerous with regard to risk for TdP.1,5,7,11,12,20,21 
These risk factors are reported in Table 3. The vast major-
ity of patients with drug-induced TdP display at least one 
of these risk factors. In a recent study including 21 patients 
with drug-induced QT interval prolongation, advanced age 
(>60 years), female gender, hypertension and paroxysmal 
atrial tachyarrhythmias were the most common identifiable 
pre-existing risk factors. In this study, TdP and cardiac arrest 
events were significantly associated with a QTc interval >510 
ms.27 It has been estimated that approximately 70% of cases 
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of drug-induced TdP occur in females.28 A reduced cardiac 
repolarization reserve closely related to sex steroids has been 
proposed to explain the increased propensity of women to 
develop drug-induced TdP.27 Testosterone, by increasing IKr 
and IKur currents, shortens the QT interval and reduces the 
risk of TdP in males.29 Polypharmacy should also be considered 
as a risk factor for drug-induced LQTS. We have recently 
shown that potential drug-interactions involving inhibition of 
cytochrome P450 isoenzymes were considered responsible in 
24% of cases.27 An analysis of medication lists from 1.1 mil-
lion patients have shown that 22.8% were taking at least one 
medication with potential for QT prolongation, 9.4% were 
taking two such medications, and 0.7% were taking three or 
more QT-prolonging drugs. Psychotropic drugs were involved 
in 50% of cases.30
T R e A T M e N T
The management of drug-induced TdP requires the 
identification and withdrawal of the suspicious medication. 
Administration of intravenous magnesium sulphate (2 g bolus 
followed by an infusion of 2-4 mg/minute) is the treatment of 
choice regardless of serum level.20,31 Similarly, correction of po-
tassium concentration (4.5-5 mmol/l) is considered important.20 
In cases of hemodynamically unstable polymorphic ventricular 
tachycardia, immediate non-synchronized defibrillation is 
indicated.20 Temporary pacing is indicated in cases refractory 
to magnesium sulfate or when TdP is precipitated by a pause 
or bradycardia.32 Pacing (90-110 beats/min) is highly effective 
in preventing recurrences.20,32 Intravenous administration of 
isoproterenol may be useful if temporary pacing is unavail-
able.33 Furthermore, the torsadogenic potential of certain 
agents can be eliminated or minimized by other drugs. In a 
recent study, esmolol added to ibutilide eliminated TdP epi-
sodes related to ibutilide monotherapy.34 Also other studies 35,36 
have suggested possible attenuation of ibutilide-induced QT 
prolongation without a decrease in ibutilide efficacy by prior 
or concomitant use of class IC agents, suggesting that these 
agents block slow inward sodium current (INa) in addition to 
fast INa. General recommendations to prevent TdP related 
to drug-induced long QT syndrome are included in Table 4.
C O N C L U S I O N
Drug-induced LQTS should always be considered as a 
predictor of sudden cardiac, and thus should prompt critical 
revaluation of the risks and benefits of the suspicious medi-
cation. In clinical practice, adverse effects of QT-prolonging 
drugs can be prevented by not exceeding the recommended 
dose; by restricting the dose in patients with pre-existing risk 
factors; and by avoiding concomitant administration of agents 
that inhibit the metabolism of known drugs that prolong the 
QT interval. Survivors of drug-induced TdP and family mem-
bers of drug-induced TdP fatalities require careful examination 
and possibly genetic testing for the presence of congenital 
LQTS-associated channelopathy.
TABLe 4. Recommendations to prevent torsades de pointes 
related to drug-induced long QT syndrome.
Preventative management
Withdrawal of any offending drugs if possible 
Correction of underlying electrolyte abnormalities
Intravenous magnesium
Cardiac pacing (90-110 bpm)
Isoproterenol infusion if temporary pacing is unavailable
TABLe 3. Risk factors for drug-induced long QT syndrome.
Risk factors
Female gender
Advanced age
Electrolyte imbalances (hypokalemia, hypomagnesemia, 
hypocalcemia)
Bradycardia
Congestive heart failure
Cardiomyopathies
Cardiac hypertrophy
Anorexia nervosa, starvation
Hypothermia
Hypothyroidism
Renal and liver insufficiency
Cytochrome P450 isoenzyme CyP3A4 inhibitors 
Baseline QT interval prolongation
Ion channel mutations/polymorphisms
Polypharmacy
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